Use of Antiasthmatic Drugs during Pregnancy after the First Trimester and Maternal and Neonatal Outcomes
Table 3
Diagnoses among women who filled prescriptions for antiasthmatic drugs during the 2nd-3rd trimester of pregnancy. Odds ratios (OR) or risk ratios (RR) with 95% confidence intervals (95% CI) adjusted for year of delivery, maternal age, parity, smoking, and BMI. Bold text marks statistical significance.
Diagnosis
With drug
In population
OR/RR
95% CI
Preexisting diabetes
69
1687
1.15
0.90–1.47
Preexisting hypertension
87
1543
1.29
1.03–1.61
Gestational diabetes
175
3929
1.05
0.89–1.23
Preeclampsia
644
13701
1.33
1.27–1.44
Hyperemesis gravidarum
36
710
1.50
1.06–2.10
Placenta previa
68
1312
1.48
1.16–1.90
Placenta abruption
64
1337
1.37
1.03–1.72
Premature rupture of membranes
205
6162
0.97
0.84–1.12
Bleeding around delivery
912
24855
1.11
1.03–1.14
Primary weak contractions
375
9738
1.12
1.01–1.25
Induction of delivery
1830
44006
1.24
1.18–1.31
Caesarean section
2319
56198
1.23
1.17–1.29
Instrumental vaginal delivery
849
24799
1.16
1.08–1.25
Among 8242 vaginal deliveries after antiasthmatic drugs and 271803 in population.
